The non-dilutive funding opportunities are updated thanks to the FFund team. Last update: Dec 18, 2023. If any question, please contact Lorina Gjonaj, COO – M +316 347 340 00 | lorina.gjonai@ffund.nl
General non-dilutive instruments
Eurostars-3
Eurostars is a joint programme between EUREKA and the European Commission, co-funded from the national budgets of 37 Eurostars Participating States and Partner Countries and by the European Union. It aims to bring increased value to the economy, higher growth and more job opportunities. Eurostars is a funding instrument that supports innovative SMEs and project partners (large companies, universities, research organisations and other types of organisations) by funding international collaborative R&D and innovation projects. By participating, organisations can access public funding for international collaborative R&D projects in all fields. Eurostars is the largest international funding programme for SMEs wishing to collaborate on R&D projects that create innovative products, processes or services for commercialisation. Your consortium must spotlight an innovative SME as the main project participant.
Funding Name: Eurostars
Funding Organization: Eureka
Amount of funding per project: €500K per partner (varies per country)
Funding versus total project costs: 35-45% of total project costs (varies per country)
Funding type: Subsidy
Close date: 2 deadlines/year (March 14, 2024 and September 2024 – specific date still unknown)
Duration of eligible projects: 36 months
Evaluation results expected: May 2024
Scope and Eligibility criteria:
– Programme supporting R&D performing SMEs and their partners
– The development of new products, processes, and services
– The budget (excluding subcontracting) of the R&D-performing SME is equal to at least 50.00% of the total project budget
– At least 2 different partners from 2 different Eurostars countries
– No organization can be responsible for more than 75% of the total project budget.
– No participants from a given country may be responsible for more than 75% of the total project budget
– The project must be completed in 36M or fewer and the market introduction (or the start of clinical trials for life sciences projects) is planned to occur within 24M of the project’s completion
– Two application submission deadlines annually
To qualify as an innovative SME in the leading role, an organization must first comply with the EC definition of an SME. In addition, it must also meet the thresholds for dedicated R&D FTEs or turnover set by EUREKA.This and all other eligibility criteria are described in detail in the Guidelines. An explanation of the eligibility criteria imposed by the programme and the method of calculation are provided in detail in the Eligibility Guidelines.
Procedure and application process: For more information click here.
IraSME
The 33rd IraSME call for proposals for transnational R&D projects is open from 1 December 2023 until 27 March 2024. The call is organised and funded by national and regional ministries and agencies participating in the IraSME network through their respective funding programmes. IraSME enables consortia of SMEs and RTOs (not mandatory) from at least two participating countries to work together in transnational R&D projects. As a growing network of several national/regional funding authorities, IraSME issues calls for proposals for transnational cooperative research projects between SMEs and RTOs twice a year. The objective is to develop innovative products, processes or technical services which exceed the existing state of the art. The calls follow a bottom-up approach, i.e. research topics are not pre-defined but chosen by the applicants themselves. Funding is made available through national and regional programmes.
Funding Name: IraSME
Funding Organization: Eureka
Amount of funding per project: €500K per partner (varies per country)
Funding versus total project costs: 35-45% of total project costs (varies per country)
Funding type: Subsidy
Close date: 2 deadlines/year (March 27, 2024 and September 25, 2024)
Duration of eligible projects: 36 months
Evaluation results expected: May 2024
Scope and Eligibility criteria:
Generally, IraSME projects have to be research and development activities with significant technical risks to realise new or notably improve existing products, processes or technical services. The clearly describable project outcome has to show real market opportunities. Consortia of IraSME projects are as small as possible and as large as necessary. They consist of at least two SMEs from two different participating countries/regions with complementary technical expertise needed to realise the project aim. Participation in an IraSME project allows SMEs and RTOs to develop a new state of the art, build new partnerships, benefit from know-how and resources that might not be available in their country or region and get an insight into foreign markets.
– Technical/experimental development up to a prototype level.
– R&D with significant technical risks for each funded partner.
– Minimum constellation: 2 companies from 2 participating countries/regions.
– Some members fund SMEs according to the EU definition, some members fund only smaller companies or include larger companies as well. Research organisations (RTOs) are generally only eligible if cooperating with at least one eligible company from the same country/region.
IraSME projects do not draw from a dedicated overall budget. Instead they use existing funding programmes available in the IraSME member countries/regions. Conditions, budget restrictions and funding rates vary from country to country and depend on company sizes and consortium structures amongst other criteria. For a first overview, please consult the information pages on the Countries / Regions involved and/or the responsible contact person listed there. The average funding per partner is around 160 k€ but varies strongly.
Procedure and application process: For more information click here.
EIC PATHFINDER OPEN
The overall objective of the EIC Pathfinder for advanced research is to develop the scientific basis to underpin breakthrough technologies. It provides support for the earliest stages of scientific, technological or deep-tech research and development. Pathfinder projects aim to build on new, cutting-edge directions in science and technology to disrupt a field and a market or create new opportunities by realising innovative technological solutions.
Funding Name: EIC Pathfinder
Funding Organization: European Commission
Amount of funding per project: Up to €3M (total budget €136M)
Funding versus total project costs: 100% of eligible costs
Close date: March 7, 2024
Duration of eligible projects: 3-5 years
Evaluation results expected: 5 months
Scope: You should apply if you are looking for support from EIC Pathfinder Open to realise an ambitious vision for radically new technology, with potential to create new markets and/or to address global challenges. EIC Pathfinder Open supports early stage development of such future technologies (e.g., various activities at low Technology Readiness Levels from 1 to 4), based on high-risk/high-gain science towards-technology breakthrough research (including ‘deep-tech’). This research must provide the foundations of the technology you are envisioning.
Before applying to this call, you should verify that your proposal meets all the following essential characteristics (‘Gatekeepers’):
– Convincing long-term vision of a radically new technology that has the potential to have a transformative positive effect to our economy and society.
– Concrete, novel and ambitious science-towards-technology breakthrough, providing advancement towards the envisioned technology.
– High-risk/high-gain research approach and methodology, with concrete and plausible objectives.
Eligibility criteria: Your proposal must be submitted by the coordinator, on behalf of a consortium including as beneficiaries, at least three legal entities, independent from each other and each established in a different country as follows:
– at least one legal entity established in a Member State; and
– at least two other independent legal entities, each established in different Member States or Associated Countries.
For this call, the EIC considers proposals with a requested EU contribution of up to EUR 3 million as appropriate. Nonetheless, this does not preclude you to request larger amounts, if duly justified.
Procedure and application process: For more information on procedures click here.
EIC TRANSITION OPEN
EIC Transition funds innovation activities that go beyond the experimental proof of principle in laboratory. It supports both the maturation and validation of your novel technology from the lab to the relevant application environments (by making use of prototyping, formulation, models, user testing or other validation tests) as well as explorations and development of a sustainable business case and business model towards commercialisation into high potential markets.
Funding Name: EIC Transition
Funding Organization: European Commission
Amount of funding per project: Up to €2.5M (total budget €94M)
Funding versus total project costs: 100% of eligible costs
Close date: September 18, 2024
Duration of eligible projects: 3 years
Evaluation results expected: 5 months
Scope: EIC Transition projects should address, in a balanced way, both technology and market/business development, possibly including iterative learning processes based on early customer or user feedback. These activities should include, subject to the level of maturity of the technology, a suitable mix of technology development and validation activities to increase the maturity of the technology beyond proof of concept to viable demonstrators of the technology in the intended field of application (i.e., from minimum TRL 3 or TRL 4 up to Technology Readiness Level 5 to 6).
Your proposal must build on results already achieved within an eligible project that are, at least, at experimental proof of concept (TRL 3) or, ideally, technology validated in the lab level (TRL 4). Proposals building on project results at TRLs other than TRL3 or TRL4 are not eligible.
EIC Transition is restricted to proposals based on results generated by the following eligible projects:
– EIC Pathfinder projects (including projects funded under the Horizon 2020 EIC pilot Pathfinder, FET-Open, FET-Proactive, CSA and CSA Lump sum FET Innovation Launchpad, and FET Flagships calls)
– European Research Council Proof of Concept projects funded Horizon 2020 or Horizon Europe.
– Research and Innovation Actions directly 38funded under Horizon 2020 Societal challenges and Leadership in Industrial Technologies and under Horizon Europe pillar II, with an eligible TRL.
– European Defence Fund (EDF), including the Preparatory Action on Defence Research, research projects, but only for proposals which are focused on civil applications (including dual use).
Eligibility criteria: You can apply for EIC Transition either as:
– A single legal entity established in a Member State or an Associated Country (‘mono-beneficiary’) if you are a start-up, SME or research performing organisation (university, research or technology organization)
– A small consortium of two independent legal entities from two different Member States or Associated Countries, or
– A consortium of minimum three and maximum five independent legal entities.
If you are applying on the basis of an eligible project for which the grant is still active, you may apply if the project has been active for at least 12 months (i.e., the start date of the grant is more than 12 months before the date of the selected EIC Transition call cut-off).
If you are applying on the basis of an eligible project which has already been completed, you may apply within 30 months of the completion of the project (i.e. the end date of the grant for the eligible project is less than 30 months from the date of the selected EIC Transition cut-off).
Procedure and application process: For more information on procedures click here.
EIC Accelerator OPEN
The EIC Accelerator supports high-risk, high-potential small and medium-sized enterprises and innovators to help them develop and bring onto the market new innovative products, services and business models that could drive economic growth. The EIC Accelerator supports the later stages of technology development as well as scale up. The technology component of your innovation must therefore have been tested and validated in a laboratory and other relevant environment (e.g., at least Technology Readiness Level 5). The EIC Accelerator looks to support companies where the EIC support will act as a catalyst to crowd in other investors necessary for the scale up of the innovation. Selected companies receive funding and optional equity, and are offered business coaching and mentoring services to scale up their innovation idea. In addition, they receive acceleration services to connect with investors, corporates and likeminded entrepreneurs.
Funding Name: EIC Accelerator
Funding Organization: European Commission
Amount of funding per project: € 0.5-2.5M (+€0.5-15M equity)
Funding versus total project costs: 70% of eligible costs (grant part)
Close date: Deadline 2024 (March 13 and October 3)
Duration of eligible projects: 12-24 months (maximum)
Evaluation results expected: 3-6 weeks later (for 2nd and 3rd phase)
Scope: The EIC Accelerator helps you develop your business concept further into a market-ready product, service or process aligned with your company’s growth strategy. Activities could, for example, include trials, prototyping, validation, demonstration and testing in real-world conditions, and market replication. If the activity concerns a primarily technological innovation, a Technology Readiness Level (TRL) of 6-8 is envisaged for projects requesting grants-only. Projects are able to receive between € 0.5 and € 2.5 million in the form of grants. They can request a higher or lower amount when applying if justified accordingly. Projects should normally take 12 to 24 months to complete but could be longer in exceptional and well-justified cases.
Since 5 June 2019 the EIC Accelerator offers blended finance in the form of an optional investment in equity in addition to the grant, to single for-profit SMEs. Grants will finance activities from TRL 6-8. Activities above TRL 8 will be funded through equity. The equity part is optionable when applying for the EIC Accelerator. The maximum of investment in the form of equity is € 15 million.
The EIC Accelerator provides:
a) grant component only (‘Grant Only’) that will take the form of a lump sum contribution via a grant agreement. Grant only shall be provided only once to any legal entity for the duration of the Horizon Europe programme (2021- 27).
b) blended finance support which is composed of:
– An investment component usually in the form of direct equity or quasi-equity such as convertible loans via an investment agreement.
– A grant component, that will take the form of a lump sum contribution via a grant agreement.
c) investment component only (Equity-Only) support to non-bankable SMEs, including start-ups, which have already received an eligible grant support, via an investment agreement.
Eligibility criteria: The EIC Accelerator is designed for small and medium-sized enterprises (SMES) with radically new ideas underpinned by a business plan for rolling out marketable innovation solutions and with ambitions to scale up. It targets for-profit SMEs only, including young companies and start-ups, from any sector – there are no set topics. The EIC Accelerator is designed for small and medium-sized enterprises (SMES) with radically new ideas underpinned by a business plan for rolling out marketable innovation solutions and with ambitions to scale up. It targets for-profit SMEs only, including young companies and start-ups, from any sector – there are no set topics.
To be an eligible applicant to EIC Accelerator, you must apply as one of the following eligible entities:
– a single company classified as a SME, and established within a Member State or an Associated Country; or
– a single company classified as a small mid-cap (up to 499 employees) established in a Member State or an Associated Country, but only for exceptional cases for rapid scale up purposes; or
– one or more natural persons (including individual entrepreneurs) or legal entities.
Large corporates, research centers or scientists cannot apply directly but they can participate in projects as subcontractors or third parties and don’t need to be established in an EU Member State or associated country.
Procedure and application process: For more information on procedures click here
The application process consists of a number of steps:
1. Short proposals which may be submitted at any time and which will be evaluated remotely by EIC expert evaluators on a first come, first served basis;
2. If successful, you will be invited to prepare a full proposal, where you will have access to support from EIC business coaches to develop your business plan;
3. Full proposals will first be assessed remotely by EIC expert evaluators. If successful, you will be invited to an interview with an EIC jury as the final step in the selection process;
4. If selected for (potential)funding, you will be invited to negotiate a grant agreement for the requested grant component (if you have applied for it) and to start the due diligence for the investment component (if you have applied for it).
EIC Accelerator challenge: Monoclonal antibody-based therapeutics for new variants of emerging viruses.
The EIC Accelerator supports high-risk, high-potential small and medium-sized enterprises and innovators to help them develop and bring onto the market new innovative products, services and business models that could drive economic growth. The EIC Accelerator supports the later stages of technology development as well as scale up. The technology component of your innovation must therefore have been tested and validated in a laboratory and other relevant environment (e.g.,at least Technology Readiness Level 5).The EIC Accelerator looks to support companies where the EIC support will act as a catalyst to crowd in other investors necessary for the scale up of the innovation. Selected companies receive funding and optional equity, and are offered business coaching and mentoring services to scale up their innovation idea. In addition, they receive acceleration services to connect with investors, corporates and likeminded entrepreneurs.
Funding Name: EIC Accelerator (€50M)
Funding Organization: European Commission
Amount of funding per project: € 0.5-2.5M (+€0.5-15M equity)
Funding versus total project costs: 70% of eligible costs (grant part)
Close date: Deadline 2024: March 13 and October 3
Duration of eligible projects: 12-24 months (maximum)
Evaluation results expected: 3-6 weeks later (for 2nd and 3rd phase)
Scope: To address this global challenge, this EIC Challenge will support the development of mAbs-based therapeutics against new variants of emerging pathogens of high concern, as a line of defence complementary to new vaccines.
Applicants to the Challenge can address:
• Broad-spectrum mAbs-based therapies.
• More effective mAbs-based therapies (e.g., address the issue of inter-individual variability).
• Clinical administration of broad spectrum mAbs-based therapeutics to outpatients with mild symptoms in overwhelmed hospitals or in dealing with hypersensitivity to treatment.
• Rapid production of mAbs-based therapies: technological innovations that can allow for the production of a mAb, including test batches during the development phase, with minimal lead time, enabling rapid availability of a product in the event of an outbreak.
• Administration of mAbs-based therapeutics: new technologies that can simplify the administration of mAbs, thereby extending the half-life of the antibody or injecting mRNA coding for a mAb.
Eligibility criteria: The EIC Accelerator is designed for small and medium-sized enterprises (SMES) with radically new ideas underpinned by a business plan for rolling out marketable innovation solutions and with ambitions to scale up. It targets for-profit SMEs only, including young companies and start-ups, from any sector – there are no set topics.
To be an eligible applicant to EIC Accelerator, you must apply as one of the following eligible entities:
– a single company classified as a SME, and established within a Member State or an Associated Country; or
– a single company classified as a small mid-cap (up to 499 employees) established in a Member State or an Associated Country, but only for exceptional cases for rapid scale up purposes; or
– one or more natural persons (including individual entrepreneurs) or legal entities.
Large corporates, research centers or scientists cannot apply directly but they can participate in projects as subcontractors or third parties and don’t need to be established in an EU Member State or associated country.
Procedure and application process: For more information click here. Please note that short application can be submitted any time.
HORIZON-HLTH-2024-DISEASE-08-20: Pandemic preparedness and response: Hostpathogen interactions of infectious diseases with epidemic potential
This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination 3 “Tackling diseases and reducing disease burden”. To that end, proposals under this topic should aim for delivering results that are directed, tailored towards and contributing to all of the following expected outcomes:
– The scientific and clinical communities have an increased knowledge on viruses with epidemic potential and in particular a better understanding of pathogen–host interactions for the targeted development of vaccines and inhibitors for the prevention of viral infection and the viral transmission during pathogenesis.
– The scientific and clinical communities have access to novel approaches for the prevention and treatment for emerging and re-emerging infections in the context of epidemic and pandemic preparedness.
– The scientific and clinical communities have access to experimental vaccine candidates and candidates that inhibit cellular uptake of viruses against emerging or re-emerging viral infections for further clinical investigation.
– A diverse and robust development pipeline of vaccine candidates and candidates that inhibit cellular uptake of viruses is available to fight emerging and re-emerging viral infections, increasing therapeutic options for clinical deployment in case of an epidemic or pandemic.
Funding Name: HORIZON-RIA HORIZON Research and Innovation Actions (single stage)
Funding Organization: European Commission
Amount of funding per project: € 8-10M (Total budget €30M)
Funding versus total project costs: 100%
Close date: April 11, 2024
Duration of eligible projects: Typically 4-5 years
Evaluation results expected: Typically 5 months
Scope: Viral disease emergence is expected to accelerate due to among other factors, climate change, and thus a proactive approach to the development of vaccines and inhibitors for the cellular uptake of viruses in preparedness for future infectious disease outbreaks is needed. The availability of vaccines and candidates that inhibit cellular uptake of viruses would provide a critical preparedness measure against future health threats, in particular against pathogens with high pandemic potential meeting the criteria identified by the Health Emergency Preparedness and Response Authority (HERA).
Proposals should follow innovative approaches to characterise host-pathogen interactions with a view to inhibit viral replication, viral proteases, viral exit strategies and to develop therapeutic antibodies and vaccines that target viruses with high epidemic or pandemic potential for the EU.
Proposals should focus on the following viruses: Hendra and Nipah virus, Lassa virus, Crimean Congo haemorrhagic fever virus, Rift Valley fever virus, Ebola and Marburg virus, Dengue virus, Yellow Fever virus, Zika virus, West Nile fever virus and Chikungunya virus.
Proposals should aim to diversify and accelerate the global therapeutic research and development pipeline for emerging and re-emerging viral infections, and to strengthen the current leading role of the EU in therapeutic research and development, and therefore contributing to the work of the European Health Emergency Preparedness and Response Authority (HERA).
Proposals should address several of the following areas:
• Identification and characterisation of receptors on the host cell that enable the docking and internalisation of a virus with a particular emphasis on the diversity of cellular entry receptors and tissue specificity.
• Identification and characterisation of viral surface proteins that are capable of interacting with host target cells.
• Characterisation of the mechanism of viral uptake in the host cell with regard to the topology and the dynamics of the host receptor – virus ligand interaction.
• Identification of receptor and ligand (sub)units that could be targeted by preventive or therapeutic intervention.
Eligibility criteria: –
Procedure and application process: For more information click here.
HORIZON-CL4-2024-RESILIENCE-01-36: Advanced biomaterials for the Health Care (IA)
This topic refers to the innovation market for Healthcare and Medicine, which affects many citizens and their needs. Several materials specifications and related innovations needs will support this topic such as renewable and recyclable materials, alternative active ingredients, design for circularity, lightweight materials. The topic should address several key policies of the European Union such as Circular Economy Action Plan, EU Chemicals strategy.
Projects are expected to contribute to the following outcomes:
• Develop the swiftly growing innovation market of medical applications, which is dependent on advanced biocompatible materials that can be printed or injected, including 4D materials that change their 3D structures following external impact (e.g. thermic, electric, mechanical or radiation treatment).
• Medical and/or surgical procedures will benefit from injectable materials for non-invasive surgical procedures.
• Some of their advantages include easy deliverability into the body, increased implantation precision, controllable release of therapeutic agents, antimicrobial properties and the possibility of monitoring or stimulating biological events. Medical suppliers can commercialise injectable hydrogels, including those made of nanocomposite, natural and synthetic polymer-based biomaterials, bone cements, bioceramics and electronics.
Funding Name: HORIZON-IA HORIZON Innovation Actions
Funding Organization: European Commission
Amount of funding per project: € 8-10M (Total budget €30M)
Funding versus total project costs: 100%
Close date: Opening January 2024 – February 7, 2024 (First Stage), September 24 (Second Stage)
Duration of eligible projects: Typically 4-5 years
Evaluation results expected: Typically 5 months
Scope: Proposals should address at least four of the following activities:
• To enable a fast development of new advanced novel injectable biomaterials, digital tools such as modelling, simulation and characterisation techniques (including those provided by analytical infrastructures) assisted by advanced methods e.g. physics-based methods, machine learning or artificial intelligence.
• The innovation market of medical applications is fast growing and dependent on advanced biocompatible materials that can be printed or injected. The 4D materials will change their 3D structures after external impact such as thermic, electric, mechanical or radiation treatment.
• Proposals shall demonstrate new engineering strategies that present functional characteristics beyond bio-compatibility, and express properties that can be used to control the physiological environment (shape-memory, self-healing properties) and induce a response.
• Proposals shall address biomaterials with antibacterial properties contributing to the widespread bottleneck of antimicrobial resistance often encountered in clinical care.
• Demonstrate the scaling of injectable hydrogels, including those made of nanocomposite, natural and synthetic polymer-based biomaterials, bone cements, bioceramics and electronics.
• The design for circularity has to develop, when relevant, bio-degradable or bioabsorbable biomaterials that are gradually eliminated by the body after fulfilling a purpose.
Proposals submitted under this topic should include a business case and exploitation strategy, as outlined in the introduction to this Destination.
Indicative budget: €6-8M per project proposal
Eligibility criteria: Activities are expected to start at TRL 3-4 achieve TRL 5-6 by the end of the project.
Procedure and application process: For more information click here.
Long-term engaging institutions and programmes
barda
Biomedical Advanced Research and Development Authority (BARDA), part of the HHS Office of the Assistant Secretary for Preparedness and Response, was established to aid in securing our nation from chemical, biological, radiological, and nuclear (CBRN) threats, as well as from pandemic influenza (PI) and emerging infectious diseases (EID). BARDA supports the transition of medical countermeasures such as vaccines, drugs, and diagnostics from research through advanced development towards consideration for approval by the FDA and inclusion into the Strategic National Stockpile. BARDA will draw on its extensive experience of successfully advancing promising medical countermeasures through late-stage development and provide $30 million during the project’s first year and up to $250 million during the five-year program.
Funding Name: Broad Agency Announcement (BAA)
Funding Organization: BARDA
Amount of funding per project: € No maximum
Funding versus total project costs: 100%
Close date: None
Duration of eligible projects: Up to 5 years
Evaluation results expected: Unspecified
Scope: Due to the COVID-19 response, any white papers or full proposal submissions, other than those that are in support of COVID-19, will be put into a queue. Once the response to COVID-19 has subsided, we will resume normal review of submissions for other research areas of interest. BARDA will not be able to meet the timelines highlighted in the Broad Agency Announcement.
COVID-19 response related Areas of Interest includes:
• AOI 7.7.1 Diagnostic Assay for Human Coronaviruses
• AOI 7.7.2 Diagnostic Assay for Detection of SARS-CoV-2 Virus
• AOI 7.7.3 Diagnostic Assay for Detection of COVID-19 Neutralizing Antibodies
• AOI 7.7.5 Screening Tests at Point of Care (2-minute Time to Result)
• AOI 9.2 COVID-19 Therapeutics
• AOI 17 Advanced Manufacturing Technologies
Eligibility:
Applicants can be from any country.
Applicants may include single entities or teams from private sector organizations, government laboratories, and academic institutions.
Procedure and application process: For more information click here.
carb-x
Co-founded by BARDA, CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) is a global non-profit partnership funding new antibiotics, vaccines, rapid diagnostics, and other products to prevent, diagnose and treat life-threatening bacterial infections. CARB-X’s Global Accelerator Network provides business, scientific, and technical expertise to CARB-X-funded product developers to support their antibacterial research projects focused on the most serious drug-resistant bacteria identified by the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC).
Funding Name: CARB-X
Funding Organization: CARB-X
Amount of funding per project: Total budget €480M
Funding versus total project costs: Unspecified
Close date: Unspecified
Duration of eligible projects: Unspecified
Evaluation results expected: Unspecified
Scope: The scope of CARB-X is to target drug-resistant bacteria highlighted on the ‘Antibiotic Resistant Threats in the United States’ report published by the CDC in 2013 or the Priority Bacterial Pathogens list published by the WHO in 2017 – with a priority on those pathogens deemed Serious or Urgent on the CDC list or Critical or High on the WHO list.
Eligibility:
There are currently no new funding rounds scheduled at the moment.
Procedure and application process: For more information click here.
InnovFin Infectious Diseases
The InnovFin Infectious Diseases Finance Facility (IDFF) provides financial products ranging from standard debt to equity-type financing for amounts typically between €7.5 million and €75 million, to innovative players active in developing innovative vaccines, drugs, medical and diagnostic devices or novel research infrastructures for combatting infectious diseases.
Funding Name: InnovFin Infectious Disease
Funding Organization: European Investment Bank
Amount of funding per project: €7.5-75M
Funding versus total project costs: Unspecified
Close date: Unspecified
Duration of eligible projects: Unspecified
Evaluation results expected: Unspecified
Scope: Project costs may include clinical trial costs, set-up of commercialisation such as market access, development of prototypes or industrial roll-out of novel equipment, pre-clinical R&D costs and working capital requirement.
The product is being made available directly through the European Investment Bank.In addition, it should have passed successfully through the pre-clinical stage or through the proof-of-concept stage (in the case of medical and diagnostic devices). Funding can be invested in research infrastructure that provides facilities, resources and related services for use by the scientific community to conduct top-level research in the ID field.
Eligibility:
To be eligible for InnovFin Infectious Diseases Finance Facility (IDFF) funding, counterparties must comply with the following criteria:
The promoter should be a large pharmaceutical company, a mid-cap or a small and medium-sized enterprise (SME), a research institute/organisation, a university, a non-profit entity or a special-purpose vehicle (SPV). Promoters, sponsors and/or operators must be willing to substantially co-fund the project.
Procedure and application process: For more information click here.